Company / Revenue per Share
ADMA Biologics, Inc. Revenue per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue per Share
$2.16
FY2025
5-year range
$0.41 / $2.16
FY2021-FY2025
Trend
+14.3%
vs FY2024
Sector context
#84 of 154
Health Care
What the data says
At $2.16, ADMA Biologics, Inc.'s revenue per share ranks #84 of 154 in the Health Care sector. Revenue per Share has increased for 3 consecutive years, from $0.41 in FY2022 to $2.16 in FY2025.
Based on SEC 10-K filings.
2.16 in FY2025 with a 5-year CAGR of +24.8%.
Improved from $1.16 to $2.16 over the past 2 years.
Health Care sector context is included.
Revenue per Share over time
Growth rates
- 3-Year CAGR
- +73.4%
- 5-Year CAGR
- +24.8%
- 10-Year CAGR
- -
Sector benchmark
#84 of 154 in Health CareTop 55% of 154This company $2.16 Sector average $10.35
▼
-79.2% below sector average
Key checks
Key Insights
- ADMA Biologics, Inc.'s revenue per share has grown for 3 consecutive years.
- In FY2025, revenue per share increased 14.3% year-over-year.
- Ranks #84 out of 154 companies in the Health Care sector.
- Lowest revenue per share in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score 3.37 (safe zone, above 2.9 threshold)
- Strong profit margin: 46.4%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Revenue per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.16 | +14.3% |
| FY2024 | $1.89 | +62.1% |
| FY2023 | $1.16 | +181.6% |
| FY2022 | $0.41 | -46.4% |
| FY2021 | $0.77 | +8.4% |
| FY2020 | $0.71 | +12.4% |
| FY2019 | $0.63 | +36.9% |
| FY2018 | $0.46 | -44.1% |
| FY2017 | $0.83 | -16.9% |
| FY2016 | $1.00 | +56.3% |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026